DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS A small clinical study found that BCG vaccination increased immune responsiveness in blood and cerebrospinal fluid without increasing inflammation in older adults. The findings suggest a possible biological mechanism linking BCG exposure to lower Alzheimer’s risk, though no clinical outcomes were assessed.
Clinical Considerations
- Immune cell responsiveness increased in both CSF and blood after BCG vaccination without corresponding rises in inflammatory markers.
- Among participants without Alzheimer’s pathology, beta‑amyloid decreased in CSF and increased in blood, suggesting altered protein distribution.
- No biomarker changes occurred in participants with existing Alzheimer’s pathology, indicating potential timing sensitivity of the effect.
- The study included 23 adults aged ≥55 years with no placebo control, limiting causal interpretation and generalizability.
Practice Applications
- Recognize this as early, hypothesis‑generating evidence linking immune modulation to Alzheimer’s biology
- Interpret biomarker changes cautiously, as clinical outcomes or disease modification were not assessed
- Avoid extrapolating BCG vaccination as a preventive strategy outside established indications
- Monitor emerging trials evaluating immune‑based approaches in neurodegenerative disease
